LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

NCT01085136 ·Status: COMPLETED ·Phase: PHASE3

Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection

NCT02199886 ·Status: TERMINATED ·Phase: PHASE1

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

NCT04268550 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer

NCT02733250 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen

NCT02475382 ·Status: NO_LONGER_AVAILABLE

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

NCT00708448 ·Status: COMPLETED ·Phase: PHASE1

Expanded Access to Rovalpituzumab Tesirine

NCT03503890 ·Status: NO_LONGER_AVAILABLE

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT02132884 ·Status: TERMINATED ·Phase: NA

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC

NCT05691829 ·Status: TERMINATED ·Phase: PHASE2

Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects

NCT04939662 ·Status: COMPLETED ·Phase: PHASE2

Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma

NCT03307759 ·Status: TERMINATED ·Phase: PHASE1

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

NCT06064500 ·Status: APPROVED_FOR_MARKETING

A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

NCT07203053 ·Status: RECRUITING ·Phase: PHASE2

Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer

NCT02204059 ·Status: COMPLETED ·Phase: PHASE1

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

NCT00553800 ·Status: COMPLETED ·Phase: PHASE2

Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

NCT02448303 ·Status: COMPLETED ·Phase: PHASE2

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

NCT00548093 ·Status: COMPLETED ·Phase: PHASE2

Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost

NCT06627738 ·Status: RECRUITING ·Phase: PHASE2

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

NCT06555263 ·Status: WITHDRAWN ·Phase: PHASE2

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

NCT03396497 ·Status: UNKNOWN ·Phase: PHASE1

Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

NCT02733159 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

NCT02318368 ·Status: TERMINATED ·Phase: PHASE2

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

NCT02323126 ·Status: TERMINATED ·Phase: PHASE2

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

NCT01222572 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

NCT00445848 ·Status: COMPLETED ·Phase: PHASE2